Zywie LLC Information

Zywie LLC is a therapeutics company focused on the treatment of metabolic and neurodegenerative disorders known as Lysosomal Storage Diseases (LSDs), a multi-billion dollar market. Many of these disorders are characterized by protein misfolding, instability and impaired trafficking of proteins within cells. One approach to treatment is the application of pharmacological chaperones (PCs), small molecules that enter cells and serve as a molecular scaffolding in order to cause misfolded mutant proteins to fold and route correctly within the cell. Zywie's lead candidate, known as "Ziva", is a pharmaceutical chaperone that targets the molecules that enter cells and serve as a molecular scaffolding in order to cause misfolded mutant proteins to fold and route correctly within the cell. Zywie is:We are developing Ziva for Parkinson's GBA carriers and are discussing clinical trials with the FDA. Developing Ziva as the first approved treatment of Type 3 (T3) Gaucher Disease (GD)Evaluating the potential to pursue approval for other indications.